Related Experiment Videos
p53 gene mutation in recurrent superficial bladder cancer
I Yoshimura1, J Kudoh, S Saito
1Department of Urology, Keio University School of Medicine, Tokyo, Japan.
The Journal of Urology
|May 1, 1995
Summary
Mutations in the p53 tumor suppressor gene (p53) may indicate a higher risk of bladder cancer recurrence. Detecting p53 gene mutations could help predict poor prognosis in patients with superficial bladder tumors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Transitional cell carcinoma (TCC) is the most common type of bladder cancer.
- Superficial, low-grade bladder tumors have a risk of recurrence.
- The p53 tumor suppressor gene plays a crucial role in cell cycle regulation and apoptosis.
Purpose of the Study:
- To investigate the association between p53 gene mutations and the prognosis of superficial bladder transitional cell carcinoma.
- To determine if p53 gene mutations can predict recurrence and progression of bladder cancer.
Main Methods:
- Surgical specimens from 30 patients with superficial, low-grade bladder TCC were analyzed.
- Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) was used to detect p53 gene mutations.
- Patient follow-up included monitoring for tumor recurrence over 24 months.
Main Results:
- Four out of 30 patients (13.3%) had p53 gene mutations in their primary bladder tumors.
- Three of the four patients with p53 mutations experienced tumor recurrence.
- Recurrent tumors in patients with p53 mutations were often invasive or high-grade.
- Two recurrent tumors showed identical p53 mutations as their primary tumors, suggesting clonal evolution.
Conclusions:
- p53 gene mutations are associated with an increased risk of poor prognosis in superficial bladder cancer.
- The presence of p53 mutations may serve as an early indicator of aggressive tumor behavior.
- p53 gene mutation analysis could be a valuable tool for risk stratification and personalized treatment of bladder cancer patients.